Annual CFF
$3.12 M
-$71.71 M-95.83%
31 December 2023
Summary:
Solid Biosciences annual cash flow from financing activities is currently $3.12 million, with the most recent change of -$71.71 million (-95.83%) on 31 December 2023. During the last 3 years, it has fallen by -$131.86 million (-97.69%). SLDB annual CFF is now -97.69% below its all-time high of $134.99 million, reached on 31 December 2021.SLDB Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$3.26 M
-$1.74 M-34.88%
30 September 2024
Summary:
Solid Biosciences quarterly cash flow from financing activities is currently $3.26 million, with the most recent change of -$1.74 million (-34.88%) on 30 September 2024. Over the past year, it has increased by +$2.75 million (+544.75%). SLDB quarterly CFF is now -97.59% below its all-time high of $135.15 million, reached on 31 March 2021.SLDB Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$116.00 M
+$3.26 M+2.89%
30 September 2024
Summary:
Solid Biosciences TTM cash flow from financing activities is currently $116.00 million, with the most recent change of +$3.26 million (+2.89%) on 30 September 2024. Over the past year, it has increased by +$112.88 million (+3615.63%). SLDB TTM CFF is now -56.04% below its all-time high of $263.85 million, reached on 31 March 2021.SLDB TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SLDB Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +544.8% | +3615.6% |
| 3 y3 years | -97.7% | +4833.3% | -14.1% |
| 5 y5 years | -94.6% | +1234.5% | +100.4% |
SLDB Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -97.7% | at low | -97.0% | >+9999.0% | -14.1% | >+9999.0% |
| 5 y | 5 years | -97.7% | at low | -97.6% | +1234.5% | -56.0% | >+9999.0% |
| alltime | all time | -97.7% | at low | -97.6% | +445.3% | -56.0% | >+9999.0% |
Solid Biosciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.26 M(-34.9%) | $116.00 M(+2.9%) |
| June 2024 | - | $5.00 M(-95.3%) | $112.75 M(+2.2%) |
| Mar 2024 | - | $107.24 M(>+9900.0%) | $110.36 M(+3435.0%) |
| Dec 2023 | $3.12 M(-95.8%) | $505.00 K(>+9900.0%) | $3.12 M(-96.0%) |
| Sept 2023 | - | $0.00(-100.0%) | $77.35 M(+0.0%) |
| June 2023 | - | $2.62 M(>+9900.0%) | $77.35 M(+3.4%) |
| Mar 2023 | - | $0.00(-100.0%) | $74.81 M(-0.0%) |
| Dec 2022 | $74.83 M(-44.6%) | $74.74 M(<-9900.0%) | $74.83 M(>+9900.0%) |
| Sept 2022 | - | -$1000.00(-101.4%) | $160.00 K(-2.4%) |
| June 2022 | - | $73.00 K(+231.8%) | $164.00 K(-211.6%) |
| Mar 2022 | - | $22.00 K(-66.7%) | -$147.00 K(-100.1%) |
| Dec 2021 | $134.99 M(+4.9%) | $66.00 K(+2100.0%) | $134.99 M(-48.8%) |
| Sept 2021 | - | $3000.00(-101.3%) | $263.62 M(+0.0%) |
| June 2021 | - | -$238.00 K(-100.2%) | $263.62 M(-0.1%) |
| Mar 2021 | - | $135.15 M(+5.0%) | $263.85 M(+105.0%) |
| Dec 2020 | $128.70 M | $128.70 M(>+9900.0%) | $128.70 M(<-9900.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | $0.00(0.0%) | -$287.00 K(-100.5%) |
| June 2020 | - | $0.00(0.0%) | $57.88 M(0.0%) |
| Mar 2020 | - | $0.00(-100.0%) | $57.88 M(0.0%) |
| Dec 2019 | $57.88 M(-56.0%) | -$287.00 K(-100.5%) | $57.88 M(-0.5%) |
| Sept 2019 | - | $58.16 M(>+9900.0%) | $58.15 M(<-9900.0%) |
| June 2019 | - | $0.00(0.0%) | -$13.00 K(-93.7%) |
| Mar 2019 | - | $0.00(-100.0%) | -$206.00 K(-100.2%) |
| Dec 2018 | $131.51 M(+70.6%) | -$13.00 K(<-9900.0%) | $131.51 M(-29.0%) |
| Sept 2018 | - | $0.00(-100.0%) | $185.28 M(+0.5%) |
| June 2018 | - | -$193.00 K(-100.1%) | $184.33 M(+0.2%) |
| Mar 2018 | - | $131.71 M(+145.0%) | $183.97 M(+138.7%) |
| Dec 2017 | $77.08 M(+2153.7%) | $53.76 M(-5800.6%) | $77.08 M(+230.5%) |
| Sept 2017 | - | -$943.00 K(+69.0%) | $23.32 M(-3.9%) |
| June 2017 | - | -$558.00 K(-102.2%) | $24.26 M(-2.2%) |
| Mar 2017 | - | $24.82 M | $24.82 M |
| Dec 2016 | $3.42 M(-93.4%) | - | - |
| Dec 2015 | $51.59 M | - | - |
FAQ
- What is Solid Biosciences annual cash flow from financing activities?
- What is the all time high annual CFF for Solid Biosciences?
- What is Solid Biosciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Solid Biosciences?
- What is Solid Biosciences quarterly CFF year-on-year change?
- What is Solid Biosciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Solid Biosciences?
- What is Solid Biosciences TTM CFF year-on-year change?
What is Solid Biosciences annual cash flow from financing activities?
The current annual CFF of SLDB is $3.12 M
What is the all time high annual CFF for Solid Biosciences?
Solid Biosciences all-time high annual cash flow from financing activities is $134.99 M
What is Solid Biosciences quarterly cash flow from financing activities?
The current quarterly CFF of SLDB is $3.26 M
What is the all time high quarterly CFF for Solid Biosciences?
Solid Biosciences all-time high quarterly cash flow from financing activities is $135.15 M
What is Solid Biosciences quarterly CFF year-on-year change?
Over the past year, SLDB quarterly cash flow from financing activities has changed by +$2.75 M (+544.75%)
What is Solid Biosciences TTM cash flow from financing activities?
The current TTM CFF of SLDB is $116.00 M
What is the all time high TTM CFF for Solid Biosciences?
Solid Biosciences all-time high TTM cash flow from financing activities is $263.85 M
What is Solid Biosciences TTM CFF year-on-year change?
Over the past year, SLDB TTM cash flow from financing activities has changed by +$112.88 M (+3615.63%)